

7:00 am Pre-Registration
7:00 am – 8:00 am EXHIBIT HALL OPEN
 8:00 am – 8:15 am Welcome & Introduction | Pre-CME Questions

SESSION 1 Has the Beta Cell Been Forgotten?
 Chair: Ralph DeFronzo, MD

| | | |
|-------------------|---|-------------------------------|
| 8:15 am | Beta Cell Failure and T2DM: Human Studies | Muhammad Abdul-Ghani, MD, PhD |
| 8:30 am | Role of Glucotoxicity and Lipotoxicity in Beta Cell Failure | John Leahy, MD |
| 8:45 am | Role of mRNA Modifications in Regulating Islet Cell Biology | Rohit Kulkarni, MD, PhD |
| 9:00 am | Gene Mutations Play a Dominant Role in Beta Cell Failure in T2DM | Steven Kahn, MD |
| 9:15 am | Antidiabetic Agents and Prevention of Beta Cell Failure: Fact & Fiction | Ralph DeFronzo, MD |
| 9:30 am – 9:50 am | Panel Discussion and Q&A | |

SESSION 2 COVID-19 in CardioRenalMetabolism
 Chairs: Chris Guerin, MD • Christian W. Mende, MD

| | | |
|---------------------|--|--------------------------|
| 9:50 am | Cardiovascular Complications of COVID: Challenges and Insights | Michael E. Farkouh, MD |
| 10:05 am | Obesity and COVID-19 – What is the Link? | Tracey L. McLaughlin, MD |
| 10:20 am | Managing Inflammation in COVID-19 Patients Focus on Colchicine | Norman E. Lepor, MD |
| 10:35 am – 10:50 am | Panel Discussion and Q&A | |

10:50 – 11:20 am REFRESHMENT BREAK

| 11:20 am – 12:10 pm | Concurrent Sessions | MEET THE EXPERTS | (In-Person Only) |
|---------------------|-----------------------|---------------------------------|------------------|
| | Daniel Einhorn, MD | Cortisol & Metabolism | Sierra C/D |
| | Ralph DeFronzo, MD | Everything Insulin Resistance | Club Room |
| | Matthew Budoff, MD | ASCVD Diagnosis Management | Hiro Room |
| | Yehuda Handelsman, MD | DM & the Heart A Paradigm Shift | Salon 6AB |

12:15 pm – 1:15 pm LUNCH BREAK

| | | | | |
|---------------------------|---|----------------|-----------------------------|---|
| 12:20 pm - 1:05 pm | Lunch Session | Non-CME | Product Theater Hall |  |
| | Jardiance® (empagliflozin) tablets: A Review of the Latest Data | | Norman Lepor, MD | |
| | Supported by: Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC | | | |

SESSION 3 The Liver: NAFLD & NASH
 Chairs: Jennifer Green, MD • Daniel Einhorn, MD

| | | |
|-------------------|--|-----------------------|
| 1:15 pm | Diagnosis and Treatment of Patients with NAFLD/NASH – The Future | Mazen Nouredin, MD |
| 1:35 pm | The Liver and the Heart | Laurence Sperling, MD |
| 1:55 pm – 2:10 pm | Panel Discussion and Q&A | |

THURSDAY, DECEMBER 2, 2021 (cont.)

SESSION 4 CardioRenalMetabolism in Youth

Chairs: Alan R. Sinaiko, MD • Sonia Caprio, MD

| | | |
|-------------------|--|-----------------------|
| 2:10 pm | Value of Early Lipid-Lowering Interventions to Prevent Later Life Cardiovascular Disease | Andrew Moran, MD, MPH |
| 2:25 pm | Co-existence of Prediabetes and Non-Alcoholic Fatty Liver Disease in Pediatric Obesity | Sonia Caprio, MD |
| 2:40 pm | Long-term complications in youth-onset type 2 diabetes: the TODAY study | Phil Zeitler, MD, PhD |
| 2:55 pm – 3:15 pm | Panel Discussion and Q&A | |

3:15 pm – 3:45 pm REFRESHMENT BREAK

SESSION 5 Diabetes – Special Populations

Chairs: Zachary Bloomgarden, MD • Tracey L. McLaughlin, MD

| | | |
|-------------------|--|------------------------|
| 3:45 pm | LADA: Epidemiology similarities & differences from T2D/T1D – Impact on Comorbidities | Richard E. Pratley, MD |
| 4:05 pm | C-peptide Levels and CVD Outcomes in the VADT | Peter Reaven, MD |
| 4:25 pm – 4:35 pm | Panel Discussion and Q&A | |

SESSION 6 Dyslipidemia & ASCVD

Chairs: Paul S. Jellinger, MD • Matthew J. Budoff, MD

| | | |
|-------------------|--|--------------------|
| 4:35 pm | Beyond LDL-C: The Role of Dyslipidemia in ASCVD | Ron M. Krauss, MD |
| 4:55 pm | Novel Agents and Combination Therapy in Management of Dyslipidemia | Erin D. Michos, MD |
| 5:15 pm – 5:30 pm | Panel Discussion and Q&A | |

5:30 pm – 6:30 pm DAY 1 SUMMARY SESSION & POST-CME QUESTIONS

Sonia Caprio, MD • Ralph A. DeFronzo, MD • Jennifer Green, MD • Yehuda Handelsman, MD • Ronald M. Krauss, MD • Tracey L. McLaughlin, MD

6:30 pm – 7:30 pm WELCOME AND POSTER RECEPTION

7:30 pm – 8:30 pm

Dinner Session

Non-CME

An Overview of the FreeStyle Libre 2 System

Supported by: Abbott

Product Theater Hall

George Grunberger, MD



FRIDAY, DECEMBER 3, 2021

7:00 am – 8:00 am EXHIBIT HALL OPEN | Continental Breakfast

8:00 am – 8:10 am Pre-CME Questions

SESSION 7 Metabolism & WCIRDC – Joint Session

Chair: Michael A. Hill, PhD • Yehuda Handelsman, MD

| | | |
|-------------------|--|------------------------------|
| 8:10 am | Insulin Action / Insulin Resistance / Diabetes and the Heart | Dale Abel, MD, PhD |
| 8:25 am | Cardiovascular Actions and Therapeutic Potential of Novel Anti-Diabetic Agents | Michael A. Hill, PhD |
| 8:40 am | Drug Development for Cardiometabolic Disorders - Focusing on the Patient | Theodoros Kelesidis, MD, PhD |
| 8:55 am – 9:10 am | Panel Discussion and Q&A | |

FRIDAY, DECEMBER 3, 2021 (cont.)

SESSION 8 Hormones, Cytokine, & Insulin – Role in Morbidities

Chairs: Richard N. Bergman, PhD • Samuel Klein, MD

| | | |
|--------------------|--|----------------------------|
| 9:10 am | Insulin Action and Insulin Resistance in the Kidney | Gerald I. Shulman, MD, PhD |
| 9:25 am | FGF1 and Insulin Control Adipose Lipolysis by Convergent Pathways | Ronald M. Evans, PhD |
| 9:40 am | Adiponectin & Leptin Roles in Cardiometabolic Control, Diabetes, Aging and Mortality | Philipp E. Scherer, PhD |
| 9:55 am – 10:15 am | Panel Discussion and Q&A | |

10:15 am – 10:45 am REFRESHMENT BREAK

SESSION 9 Pumps, CGM, Risk Engine and Hypoglycemia

Chairs: Richard E. Pratley, MD • W. Timothy Garvey, MD

| | | |
|---------------------|---|-------------------------|
| 10:45 am | BRAVO risk Engine – Simulating Trials and Evaluating Cost | Vivian A. Fonseca, MD |
| 11:00 am | Clinical Guidelines 2021 - CGM and Insulin Pump Therapy | George Grunberger, MD |
| 11:15 am | Hypoglycemia Contemporary approach to management | Guillermo Umpierrez, MD |
| 11:30 am – 11:45 am | Panel Discussion and Q&A | |

SESSION 10 A Glimpse in the Future - What's in the Pipeline? (Non-CME)

Chairs: Ralph DeFronzo, MD • Tracey L. McLaughlin, MD

| | | |
|--------------------|--------------------------|---------------------------|
| 11:45 am | Zealand | David Kendall, MD |
| 12:00 pm | Boehringer Ingelheim | Mohamed Eid, MD, MPH, MHA |
| 12:15 pm | Corcept | Joe Belanoff, MD |
| 12:30 pm | Regeneron | Sergio Fazio, MD, PhD |
| 12:45 pm – 1:00 pm | Panel Discussion and Q&A | |

1:00 pm – 2:00 pm LUNCH BREAK

1:10 pm – 1:55 pm

Lunch Session

Non-CME

Primary Hypercortisolism: What are We Missing and Why Does it Matter?
Supported by: Corcept Therapeutics

Product Theater Hall

Daniel Einhorn, MD



SESSION 11 DCRM Multispecialty Practice Recommendations for the Management of Diabetes, Cardiorenal, and Metabolic Diseases

Chair: Yehuda Handelsman, MD

| | | |
|-------------------|--|--|
| 2:00 pm | Matthew Budoff, MD • Daniel Einhorn, MD • Vivian Fonseca, MD • Jennifer Green, MD • George Grunberger, MD • Christian Mende, MD • Erin D. Michos, MD | |
| 3:00 pm – 3:30 pm | Panel Discussion and Q&A | |

3:30 pm – 4:00 pm REFRESHMENT BREAK

SESSION 12 The Heart, Metabolism and CVOT

Chairs: Peter J. Grant, MD • Norman E. Lepor, MD

| | | |
|-------------------|---|--------------------------|
| 4:00 pm | Aortic Stenosis and Metabolic Diseases | Robert J. Chilton, DO |
| 4:15 pm | Testosterone Treatment Impact on Atherosclerosis in Men | Matthew J. Budoff, MD |
| 4:30 pm | Impact of Hormones on Cardiometabolic Health | Pam R. Taub, MD |
| 4:45 pm | Update on CVOTs | Mikhail N. Kosiborod, MD |
| 5:10 pm – 5:30 pm | Panel Discussion and Q&A | |

FRIDAY, DECEMBER 3, 2021 (cont.)

5:30 pm – 6:30 pm DAY 2 SUMMARY SESSION & POST-CME QUESTIONS

Ralph DeFronzo, MD • Yehuda Handelsman, MD • Samuel Klein, MD
Mikhail N. Kosiborod, MD • Norman E. Lepor, MD • Richard E. Pratley, MD

6:30 pm – 7:30 pm

Dinner Session

Non-CME

Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C
Supported by: Esperion Therapeutics

Product Theater Hall

Norman Lepor, MD



7:30 pm – 9:00 pm ABSTRACT ORAL PRESENTATION

Sierra C/D

Cheese & Wine

Zachary Bloomgarden, MD, Chair
Abstract Committee: Daniel Einhorn, MD • George Grunberger, MD • Philip Levy, MD
Abstracts are published in **Metabolism** Editor-in-Chief: **Christos S. Mantzoros, MD, PhD**



SATURDAY, DECEMBER 4, 2021

7:00 am – 8:00 am

Continental Breakfast

7:00 am – 7:45 am


Morning Session

Non-CME

Clinical Utility of Glycated Albumin & Validation Studies as an
Intermediate Glycemic Control Marker
Supported by: Asahi Kasei Pharma Corporation

Product Theater Hall

Cyrus Desouza, MBBS



8:00 am – 8:05 am

Abstract Oral Winner Presentation

8:05 am – 8:15 am

Pre-CME Questions

SESSION 13

Diabetes – Past, Present & Future

Chairs: George Grunberger, MD • Vivian A. Fonseca, MD

8:15 am

Insulin - 100 years of Progress

Jay S. Skyler, MD

8:30 am

The Importance of Long Term Management of Hyperglycemia

Peter J. Grant, MD

8:45 am

Early Combination Therapy in DM - Impact on Comorbidities

Jennifer Green, MD

9:00 am

Reversing Type 2 Diabetes from Day One

Julio Rosenstock, MD

9:15 am – 9:35 am

Panel Discussion and Q&A

SESSION 14

Obesity 2021 – A Paradigm Shift

Chairs: Ronald M. Krauss, MD • Matthew R. Weir, MD

9:35 am

A New Era in Obesity Medicine: Treat-to-Target

W. Timothy Garvey, MD

9:50 am

What's the Best Weight Loss Diet?

Donna H. Ryan, MD

10:05 am

Key Concepts in Treating Obesity as a Disease: A Focus on Pharmacological Interventions

Ania Jastreboff, MD, PhD

10:20 am - 10:35 am

REFRESHMENT BREAK

SATURDAY, DECEMBER 4, 2021(cont.)

GERALD REAVEN DISTINGUISHED LEADER IN INSULIN RESISTANCE – 2021 AWARD

10:35 am

2021 Award Presentation "Gerald Reaven Distinguished Leader in Insulin Resistance"

10:40 am

Why Does Obesity Cause Type 2 Diabetes

Samuel Klein, MD



11:10 am – 11:30 am Session 14 Panel Discussion and Q&A

11:30 am – 12:30 pm LUNCH BREAK

11:40 am – 12:25 pm

Lunch Session

Non-CME

Product Theater Hall

The Role of the Gut in Type 2 Diabetes: Going Beyond Incretins

Supported by: Fractyl Health



Geltrude Mingrone, MD, PhD



Randy Seeley, PhD

SESSION 15 Glucose Metabolism and Diabetes

Chairs: Philipp E. Scherer, PhD • Richard N. Bergman, PhD

12:30 pm

Insulin Resistance Impact on Insulin Clearance and Metabolic Demand Effect on Glucose Tolerance

Ralph DeFronzo, MD

12:45 pm

Statin Associated with Increased Insulin Resistance & Diabetes

Joshua W. Knowles, MD

1:00 pm – 1:10 pm

Panel Discussion and Q&A

SESSION 16 CKD, HF and ASCVD in Diabetes & Without

Chairs: Pam R. Taub, MD • Peter J. Grant, MD

1:10 pm

The Role of (Micro) Albuminuria in Predicting HF, ASCVD and CKD

Richard E. Pratley, MD

1:25 pm

The Prevention of ASCVD in Patients with Diabetes

Ildiko Lingvay, MD

1:40 pm

Update in HF Management – How Should/Would the Guidelines Look?

Mikhail N. Kosiborod, MD

1:55 pm – 2:10 pm REFRESHMENT BREAK

2:10 pm

Heart Failure today: A new epidemic or a co-morbidity

Mark Kearney, MD

2:25 pm

The Contemporary Approach to MRA, Aldosterone in the Kidney and the Heart

Christian W. Mende, MD

2:40 pm

Treatment of Diabetic Nephropathy: what does the future hold?

Robert D. Toto, MD

2:55 pm – 3:15 pm

Panel Discussion and Q&A

3:15 pm – 4:10 pm DAY 3 SUMMARY SESSION & POST-CME QUESTIONS

Richard N. Bergman, PhD • W. Timothy Garvey, MD • Peter J. Grant, MD

George Grunberger, MD • Yehuda Handelsman, MD • Pam R. Taub, MD

4:15 pm – 5:00 pm

Concurrent Sessions

CLINICAL WORKSHOPS

(In-Person Only)

Management of DM

Sierra Ballroom C/D

Yehuda Handelsman, MD

All You Wanted to Know about CGM

Sierra Ballroom B

George Grunberger, MD

Lipids

Club Room

Paul Jellinger, MD • Paul Rosenblit, MD